(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Li Auto Breaks 30K Deliveries Barrier; Stifel and Needham: Bullish View on Accolade

July 01st, 2023

Li Auto Inc. (Nasdaq: LI) achieved a significant milestone in June 2023 by delivering 32,575 vehicles, surpassing the monthly delivery mark of 30,000 for the first time. This represents an impressive year-over-year increase of 150.1%. In the secon. Read more

Nokia, Apple Ink License Deal; PT Boost for Zillow, EQT, Nike, and NVIDIA

July 01st, 2023

Nokia Oyj (NYSE: NOK) and Apple Inc. (Nasdaq: AAPL) have entered into a new patent cross-license agreement, replacing the existing license set to expire at the end of 2023. The specifics of the agreement are confidential. This license encompasses . Read more

Astrotech Snubs Takeover Bid, Analysts Bullish on ArcBest, Medtronic, Ternium

July 01st, 2023

Astrotech Corporation (Nasdaq: ASTC) has officially rejected an unsolicited acquisition proposal for $17.25 per share in cash from BML Investment Partners, L.P.  The Board of Directors unanimously determined that the proposal is opportunistic. Read more

FTC Files Amended Complaint Charging that Walmart Facilitated Scams Through Its Money Transfer Services That Fleeced Customers Out of Hundreds of Millions

July 01st, 2023

Washington D.C. / CRWE PRESS RELEASE / June 30, 2023 -  The Federal Trade Commission filed an amended complaint bolstering the agency’s case that Walmart allowed its money transfer services to be used by scammers, who f. Read more

RTX and Boeing: Major Wins in Defense Contracts

July 01st, 2023

RTX (NYSE: RTX), through its subsidiaries, has been awarded three contracts totaling $5,623,670,040. The first one, awarded to RTX's Pratt & Whitney, is a modification worth $5,500,316,404 to the F117 Engine Sustainment Support contract, bringing . Read more

UK's Digital Economy at Risk: CMA Questions Adobe's Figma Acquisition

June 30th, 2023

The Competition and Markets Authority (CMA) in the UK has expressed concerns about Adobe Inc.'s (Nasdaq: ADBE) acquisition of Figma, a leading provider of screen design and whiteboarding tools. The CMA's investigation revealed that both companies com. Read more

Breaking: Tattooed Chef's Bankruptcy, Gilead's Arcus Biosciences Stake, Apple's $3T Mark

June 30th, 2023

Tattooed Chef, Inc. (Nasdaq: TTCF) has announced its intention to file for Chapter 11 bankruptcy protection and pursue the sale of its assets.  Despite efforts to secure funding and reduce expenses, the company faced challenges in the financi. Read more

Tapping into Potential: JNPR, PSTV, DFIN, BDTX, PACB, CDW - Buy Ratings

June 30th, 2023

Juniper Networks Inc. (NYSE: JNPR), a provider of networking solutions, was initiated for coverage by Citigroup with a Buy rating and a price target of $38.  Despite closing at $30.88 on Thursday, the stated price target suggests a potential . Read more

Market Movers: Spotlight on Bright Health, Merus, and Apple

June 30th, 2023

Shares of Bright Health Group, Inc. (NYSE: BHG) witnessed a surge of over 20% in pre-market trading as it announced a definitive agreement with Molina Healthcare, Inc. (NYSE: MOH) to sell its California Medicare Advantage business, Brand New Day and . Read more

Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit

June 30th, 2023

Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more